caffeine
Approved
Nov 26, 1948
Caffeine is a methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases. Caffeine is used by mouth or rectally in combination with painkillers (such as aspirin and acetaminophen) and a chemical called ergotamine for treating migraineheadaches. It is also used with painkillers for simple headaches and preventing and treating headaches after epidural anesthesia. Caffeine creams are applied to the skin to reduce redness and itching in dermatitis. Healthcare providers sometimes give caffeine intravenously (by IV) for headache after epidural anesthesia, breathing problems in newborns, and to increase urine flow. In foods, caffeine is used as an ingredient in soft drinks, energy drinks, and other beverages. — NCATS
Clinical trial activity
409 trials · 386 clinical orgs · 73 marketing orgs
Earliest trial started Jul 1, 1995 (NCT00162383)
Timeline
1940s
- Nov 26, 1948
Earliest FDA Approval
- Nov 26, 1948
Novartis — NDA Secondary Org
1950s
- Nov 12, 1957
Xanodyne Pharmaceuticals — NDA Secondary Org
- Jul 7, 1958
Sun Pharmaceuticals — NDA Secondary Org
1960s
- Mar 4, 1964
Bausch Health Companies — NDA Secondary Org
- Mar 4, 1964
Medicis — NDA Secondary Org
1970s
- Dec 22, 1970
Sandoz — Marketing Organization
- Sep 23, 1975
Alta Pharma — Marketing Organization
- May 4, 1976
Allergan — NDA Secondary Org
- Aug 21, 1978
Watson Pharmaceuticals — Marketing Organization
- Jun 5, 1979
Hikma — Marketing Organization
- Jul 25, 1979
Actavis — Marketing Organization
1980s
- Apr 30, 1980
Puracap Pharmaceutical — Marketing Organization
- Jul 30, 1980
Fosun — Marketing Organization
- Nov 5, 1980
Organon — Marketing Organization
- Dec 28, 1981
Lannett Company, Inc. — Marketing Organization
- Oct 4, 1983
Cosette — Marketing Organization
- Nov 9, 1984
Actavis — NDA Secondary Org
- Jan 24, 1985
Specgx Llc — Marketing Organization
- Mar 27, 1985
Graham Dm — Marketing Organization
- Mar 27, 1985
Mallinckrodt — Marketing Organization
- Mar 27, 1985
Avon Products — Marketing Organization
- Mar 29, 1985
Teva — Marketing Organization
- Mar 4, 1986
Pharmaceutical Research Associates, Inc. (PRA) — Marketing Organization
- Mar 17, 1986
Dr. Reddy's Laboratories — Marketing Organization
- Mar 17, 1986
Mayne Pharma — Marketing Organization
- May 14, 1986
Leitner Pharms — Marketing Organization
- Oct 1, 1986
Shire — Marketing Organization
- Jan 21, 1987
Mikart — Marketing Organization
1990s
- Oct 26, 1990
SmithKline Beecham — NDA Secondary Org
- Nov 27, 1996
Novartis — Marketing Organization
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
- Jan 14, 1998
GlaxoSmithKline — NDA Secondary Org
- May 29, 1998
Galt Pharmaceuticals — Marketing Organization
- Aug 31, 1998
Jerome Stevens Pharmaceuticals — Marketing Organization
- Sep 21, 1999
West-Ward Pharmaceutical — NDA Secondary Org
- Sep 21, 1999
Hikma — NDA Secondary Org
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
- Jul 23, 2001
Able Laboratories — Marketing Organization
- Aug 22, 2001
Bausch Health Companies — Marketing Organization
- Nov 26, 2001
Perrigo — Marketing Organization
- Nov 30, 2001
LGM Pharma — Marketing Organization
- Apr 22, 2002
Vintage — Marketing Organization
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
- Sep 21, 2006
Exela Pharma Sciences, LLC. — Marketing Organization
- Sep 22, 2006
West-Ward Pharmaceutical — Marketing Organization
- Apr 3, 2007
Boca Pharmacal — Marketing Organization
- Apr 3, 2007
Wraser Pharmaceuticals — Marketing Organization
- May 15, 2007
Lutipold — Marketing Organization
- May 15, 2007
Sankyo — Marketing Organization
- May 15, 2007
Daiichi Sankyo — Marketing Organization
- Jun 13, 2007
Nostrum Laboratories — Marketing Organization
- Jul 20, 2007
Fresenius — Marketing Organization
- Dec 1, 2008
Novast Labs — Marketing Organization
- Dec 23, 2008
Mirror Pharms — Marketing Organization
- Sep 30, 2009
Sun Pharmaceuticals — Marketing Organization
- Nov 16, 2009
Nexgen Pharma, Inc — Marketing Organization
2010s
- Aug 29, 2012
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Sep 22, 2015
Aurobindo Pharma — Marketing Organization
- Sep 22, 2015
Eugia Pharma — Marketing Organization
- Sep 22, 2016
Pharmaceutics International, Inc. — Marketing Organization
- Sep 22, 2016
Strides Pharma Science — Marketing Organization
- Sep 22, 2016
Esteve Labs — Marketing Organization
- Sep 30, 2016
Larken Labs Inc — Marketing Organization
- Oct 28, 2016
Nuvo Research Inc. — Marketing Organization
- Jan 10, 2017
County Line — Marketing Organization
- Jan 10, 2017
Alvogen — Marketing Organization
- Aug 4, 2017
Xspire Pharma — Marketing Organization
- Dec 14, 2017
Micro Labs Ltd India — Marketing Organization
- Sep 26, 2018
Abhai LLC — Marketing Organization
2020s
- Apr 8, 2020
Granules India — Marketing Organization
- Jul 1, 2020
Taro Pharmaceuticals — Marketing Organization
- Jul 17, 2020
Nesher Pharms — Marketing Organization
- Jul 17, 2020
Zydus Discovery DMCC — Marketing Organization
- Aug 13, 2021
Senores Pharms — Marketing Organization
- Aug 13, 2021
RISE PHARMA — Marketing Organization
- Nov 17, 2021
RiconPharma — Marketing Organization
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 1
- Acute-On-Chronic Liver Failure · Phase 1
- Acute Pain · Phase 3
- Adenoidectomy · Phase 2
- Adenosine · Phase 4
- Affect · Phase 4
- Aged · Phase 4
- Alzheimer Disease · Phase 3
- Amblyopia · Phase 1/Phase 2
- Amyotrophic Lateral Sclerosis · Phase 1
- Anemia · Phase 1
- Anesthesia · Phase 4
- Anxiety · Phase 4
- Apnea · Phase 4
- Arthralgia · Phase 3
- Arthritis, Rheumatoid · Phase 1
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 3
- Attention Deficit Disorder with Hyperactivity · Early Phase 1
- Autonomic Nervous System Diseases · Phase 3
- Back Pain · Phase 3
- Brain Diseases · Phase 2
- Brain Injuries · Phase 4
- Breast Neoplasms · Phase 2
- Bronchopulmonary Dysplasia · Phase 4
- Caffeine · Phase 4
- Cannabinoids · Early Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 4
- Carcinoma, Renal Cell · Phase 4
- Cardiovascular Diseases · Phase 4
- Cellulitis · Phase 2/Phase 3
- Cerebral Intraventricular Hemorrhage · Phase 4
- Child Development · Phase 4
- Cholecystectomy, Laparoscopic · Phase 2
- Chronic Pain · Phase 1
- Cocaine-Related Disorders · Phase 4
- Cognition · Phase 4
- Cognition Disorders · Phase 4
- Cognitive Dysfunction · Phase 2
- Colitis, Ulcerative · Phase 4
- Common Cold · Phase 4
- Communicable Diseases · Phase 1
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 3
- COVID-19 · Phase 1
- Crohn Disease · Phase 4
- Cytochromes · Phase 1
- Dermatitis, Atopic · Phase 1
- Diabetes Mellitus, Type 2 · Phase 1
- Disorders of Excessive Somnolence · Phase 2/Phase 3
- Dopamine · Phase 4
- Down Syndrome · Phase 3
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Drugs, Investigational · Early Phase 1
- Dysmenorrhea · Phase 3
- Dyspnea · Phase 2
- Endothelium · Phase 4
- Endotoxemia · Phase 1
- Energy Metabolism · Phase 4
- Enhanced Recovery After Surgery · Phase 1/Phase 2
- Exercise · Phase 2/Phase 3
- Flavonoids · Early Phase 1
- Food-Drug Interactions · Phase 1
- Graft Rejection · Phase 4
- Headache · Phase 3
- Healthy Volunteers · Phase 4
- Hemodynamics · Phase 4
- Hepatitis C, Chronic · Phase 1
- HIV Infections · Phase 1
- Hypotension, Orthostatic · Phase 1
- Hypoxia · Phase 3
- Hypoxia-Ischemia, Brain · Phase 1
- Infant · Phase 2
- Infant, Premature · Phase 3
- Infant, Premature, Diseases · Phase 4
- Intermittent Claudication · Phase 3
- Intestinal Neoplasms · Phase 4
- Intubation · Phase 4
- Ischemic Stroke · Phase 1/Phase 2
- Labor Stage, Second · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Liver Diseases · Phase 1
- Low Back Pain · Phase 3
- Lung Diseases · Phase 2/Phase 3
- Meconium Aspiration Syndrome · Phase 2
- Melanoma · Phase 1
- Memory Disorders · Phase 2/Phase 3
- Metabolic Detoxication, Phase I · Phase 1
- Metabolic Side Effects of Drugs and Substances · Early Phase 1
- Metabolic Syndrome · Phase 1
- Metabolism · Phase 1
- Migraine with Aura · Phase 4
- Migraine without Aura · Phase 3
- Mitochondrial Diseases · Phase 1
- Molecular Imaging · Phase 1
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Musculoskeletal Pain · Phase 3
- Myocardial Infarction · Phase 3
- Narcolepsy · Phase 1/Phase 2
- Neck Pain · Phase 3
- Neoplasms · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2/Phase 3
- Obesity · Phase 3
- Obesity, Morbid · Phase 1/Phase 2
- Overweight · Phase 1/Phase 2
- Oxygen · Phase 4
- Parkinson Disease · Phase 3
- Performance-Enhancing Substances · Phase 2/Phase 3
- Pharmacokinetics · Phase 1
- Pharmacological and Toxicological Phenomena · Phase 4
- Pharmacology · Phase 1
- Placebo Effect · Phase 4
- Porphyria, Acute Intermittent · Phase 1
- Porphyrias · Phase 1
- Post-Dural Puncture Headache · Phase 4
- Postoperative Cognitive Complications · Phase 2
- Postoperative Complications · Phase 2
- Postoperative Pain · Phase 3
- Premature Birth · Phase 4
- Prostatic Neoplasms · Phase 1
- Psoriasis · Phase 1
- Pure Autonomic Failure · Phase 1
- Reperfusion Injury · Phase 4
- Respiratory Insufficiency · Phase 4
- Respiratory Syncytial Virus Infections · Phase 1
- Retinopathy of Prematurity · Phase 2
- Scoliosis · Phase 4
- Sexual Health · Phase 1
- Sleep Apnea, Obstructive · Phase 2
- Smoking · Phase 1
- Spinal Cord Injuries · Phase 1/Phase 2
- Sports · Phase 3
- Sports Medicine · Phase 2/Phase 3
- Substance Withdrawal Syndrome · Phase 2/Phase 3
- Syncope, Vasovagal · Phase 2
- Task Performance and Analysis · Phase 2/Phase 3
- Tension-Type Headache · Phase 2/Phase 3
- Tobacco Use Disorder · Phase 1
- Tonsillectomy · Phase 2
- Tooth Diseases · Phase 3
- Ventilators, Mechanical · Phase 4
- Vertigo · Phase 4
- Vestibular Diseases · Phase 4
- Voice Disorders · Early Phase 1
- Volunteers · Phase 1
Mechanism of action
- Adenosine receptorANTAGONIST
Adenosine receptor antagonist
- Adenosine receptor A1 (ADORA1) ↗
- Adenosine receptor A2b (ADORA2B) ↗
- Adenosine receptor A3 (ADORA3) ↗
- Adenosine receptor A2a (ADORA2A) ↗
- Adenosine A1 receptor
- Adenosine A2a receptor
- Adenosine A2b receptor
- Adenosine A3 receptor
- Adenosine A2 receptor
- Adenosine receptors; A1 & A3
- Adenosine receptors; A2a & A3
- Adenosine receptors; A2b & A3
- Adenosine receptors; A1 & A2
- Adenosine receptors; A1 & A2b
- Adenosine receptors; A1 & A2a
- Adenosine receptors; A2a & A2b
Combination products
anoquan
with acetaminophen, butalbital
Also known as esgic-plus
cafergot
with ergotamine
Also known as migergot, wigraine
darvon compoun
with acetylsalicylic acid, propoxyphene
Also known as compoun, propoxyphene compoun
dhc plus
with acetaminophen, dihydrocodeine
Also known as synalgos-dc-a, trezix
excedrin (migraine relief)
fioricet w/ codeine
with acetaminophen, codeine, butalbital
Also known as butalbital; acetaminophen; caffeine; codeine, phrenilin with caffeine and codeine
fiorinal
with acetylsalicylic acid, butalbital
Also known as lanorinal
fiorinal w/codeine
norgesic forte
with acetylsalicylic acid, orphenadrine hydrochloride
Also known as invagesic, invagesic forte, norgesic, orphengesic, orphengesic forte
synalgos-dc
Approval history
- approvedNov 26, 1948
Chemistry & pharmacology
SMILES
Cn1c(=O)c2c(ncn2C)n(C)c1=O- Mol. weight
- 194.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Over the Counter
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL113 ↗
- WikipediaCaffeine ↗
- NCATS3G6A5W338E ↗
- ChEMBLCHEMBL1200569 ↗
Also known as
- 1,3,7-trimethyl-2,6-dioxopurine
- 1,3,7-trimethyl-2,6-dioxopurine
- 1,3,7-trimethyl-2,6-dioxopurine
- 1,3,7-trimethylpurine-2,6-dione
- 1,3,7-trimethylpurine-2,6-dione
- 1,3,7-trimethylxanthine
- 1,3,7-trimethylxanthine
- 1-methyltheobromine
- 1-methyltheobromine
- 3,7-dihydro-1,3,7-trimethyl-1h-purin-2,6-dion
- 3,7-dihydro-1,3,7-trimethyl-1h-purin-2,6-dion
- 7-methyltheophylline
- 7-methyltheophylline
- 7-methyltheophylline
- acetaminophen mixture with caffeine and dipyrone
- anhydrous caffeine
- anhydrous caffeine
- anhydrous caffeine
- anhydrous caffeine
- anhydrous caffeine
- anhydrous caffeine
- cafalgine
- cafcit
- cafcit
- cafcit
- cafeina
- cafeína
- cafeína
- caféine
- caféine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine
- caffeine citrate
- caffeine citrate
- caffeine citrate
- caffeine citrate
- caffeine citrate
- caffeine citrate
- caffeine citrate
- caffeine, citrated
- caffeine, citrated
- caffeine, citrated
- caffeinol
- caffeinol
- caffeinum
- caffeinum
- citrated caffeine
- coffein
- coffein
- coffeine
- coffeine
- coffeinum
- coffeinum
- durvitan
- guaranine
- guaranine
- guaranine
- koffein
- koffein
- mateína
- mateína
- methyltheobromine
- methyltheobromine
- methyltheobromine
- nodoz
- nodoz
- nodoz caplets and chewable tablets
- nodoz caplets and chewable tablets
- nymusa
- orphenadrine caffeine
- peyona
- peyona
- peyona
- pro-plus
- teína
- teína
- thein
- thein
- thein
- theine
- theine
- theine
- yeast-vite
- zanthine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07262060 | Phase 2 | Mar 31, 2026 | National Institutes of Health (NIH), University of Wisconsin |
| NCT06978777 | N/A | Jan 15, 2026 | University of Basel |
| NCT07238465 | Phase 3 | Dec 31, 2025 | Linda Crnic Institute for Down Syndrome, National Institute on Aging (NIA), University of Colorado, Denver |
| NCT06972108 | Phase 2 | Dec 1, 2025 | University of Alberta |
| NCT07216365 | Phase 2 | Nov 1, 2025 | University of Rochester |
| NCT07212803 | Phase 4 | Nov 1, 2025 | University of the Pacific |
| NCT06972849 | N/A | Oct 31, 2025 | University of Melbourne |
| NCT07193264 | N/A | Oct 31, 2025 | — |
| NCT07305935 | N/A | Oct 1, 2025 | RESnTEC, Institute of Research |
| NCT07268573 | N/A | Aug 1, 2025 | Sinop University |
| NCT07076654 | N/A | Jul 12, 2025 | Cairo University |
| NCT06638372 | N/A | Jul 1, 2025 | National Taiwan Sport University |
| NCT06855108 | Phase 3 | Jun 30, 2025 | Aga Khan University, Bill and Melinda Gates Foundation, Columbia University, Institute of Nutrition of Central America and Panama, International Center for Diarrheal Disease Research, Jawaharlal Nehru Medical College, Lata Medical Research Foundation, Nagpur, India, National Institute of Child Health and Human Development (NICHD), RTI International, Thomas Jefferson University, University of Alabama, Birmingham, University of Colorado, Denver, University of Kinshasa, University of North Carolina at Chapel Hill, University of Virginia, University Teaching Hospital, Lusaka, Zambia |
| NCT07047105 | N/A | Jun 13, 2025 | Mibelle AG, Northumbria University |
| NCT07210099 | N/A | May 30, 2025 | Anglia Ruskin University |
| NCT06973005 | Phase 1 | May 8, 2025 | AstraZeneca, Parexel |
| NCT06935214 | N/A | May 1, 2025 | St Mary's University, Twickenham |
| NCT06939608 | N/A | Apr 28, 2025 | University of Greifswald |
| NCT06917508 | Phase 1 | Mar 13, 2025 | Enanta Pharmaceuticals |
| NCT07056231 | N/A | Mar 5, 2025 | Sinop University |
Organizations
Research & Development (386)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 14 | 13 | 3 | 1998 |
| National Institutes of Health (NIH) | Government | 9 | 0 | 4 | 2008 |
| GlaxoSmithKline | For profit | 8 | 8 | 3 | 2006 |
| National Taiwan Sport University | Academic/Hospital | 8 | 8 | 2 | 2022 |
| Radboud University | Academic/Hospital | 8 | 8 | 3 | 2003 |
| AstraZeneca | For profit | 7 | 6 | 2 | 2007 |
| Johnson and Johnson | For profit | 6 | 5 | 2 | 2004 |
| Northumbria University | Academic/Hospital | 6 | 4 | 2 | 2005 |
| United States Army | Government | 6 | 3 | 2 | 2017 |
| Universidad de Alcala, Madrid | Academic/Hospital | 6 | 6 | 1 | 2023 |
| University of Basel | Academic/Hospital | 6 | 4 | 2 | 2012 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 5 | 0 | 3 | 1999 |
| Harvard University | Academic/Hospital | 5 | 3 | 3 | 2005 |
| University of Bern | Academic/Hospital | 5 | 4 | 2 | 2010 |
| University of Chicago | Academic/Hospital | 5 | 5 | 4 | 2004 |
| University of Copenhagen | Academic/Hospital | 5 | 5 | 3 | 2000 |
| Ache Laboratorios Farmaceuticos S.A. | For profit | 4 | 4 | 1 | 2017 |
| Astellas | For profit | 4 | 3 | 3 | 1999 |
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2008 |
| Johns Hopkins University | Academic/Hospital | 4 | 3 | 2 | 2011 |
Marketing (93)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abhai LLC | For profit | MKTG | Sep 26, 2018 |
| Able Laboratories | For profit | MKTG | Jul 23, 2001 |
| Actavis | For profit | NDA2 | Nov 9, 1984 |
| Actavis | For profit | MKTG | Jul 25, 1979 |
| Allergan | For profit | NDA2 | May 4, 1976 |
| Alta Pharma | For profit | MKTG | Sep 23, 1975 |
| Alvogen | For profit | MKTG | Jan 10, 2017 |
| Aurobindo Pharma | For profit | MKTG | Sep 22, 2015 |
| Aurobindo Pharma | For profit | SYN | Sep 26, 2018 |
| Avon Products | For profit | MKTG | Mar 27, 1985 |
| Bausch Health Companies | For profit | NDA2 | Mar 4, 1964 |
| Bausch Health Companies | For profit | MKTG | Aug 22, 2001 |
| Boca Pharmacal | For profit | MKTG | Apr 3, 2007 |
| Cosette | For profit | MKTG | Oct 4, 1983 |
| Cosette | For profit | SYN | Oct 4, 1983 |
| County Line | For profit | MKTG | Jan 10, 2017 |
| Daiichi Sankyo | For profit | MKTG | May 15, 2007 |
| Dr. Reddy's Laboratories | For profit | MKTG | Mar 17, 1986 |
| Esteve Labs | For profit | MKTG | Sep 22, 2016 |
| Eugia Pharma | For profit | MKTG | Sep 22, 2015 |
| Exela Pharma Sciences, LLC. | For profit | SYN | Sep 21, 2006 |
| Exela Pharma Sciences, LLC. | For profit | MKTG | Sep 21, 2006 |
| Exela Pharma Sciences, LLC. | For profit | SYN | Sep 21, 2006 |
| Forest Laboratories | For profit | MKTG | — |
| Fosun | For profit | MKTG | Jul 30, 1980 |
| Fresenius | For profit | MKTG | Jul 20, 2007 |
| Galt Pharmaceuticals | For profit | MKTG | May 29, 1998 |
| GlaxoSmithKline | For profit | NDA2 | Jan 14, 1998 |
| Graham Dm | For profit | MKTG | Mar 27, 1985 |
| Granules India | For profit | MKTG | Apr 8, 2020 |
| Granules India | For profit | SYN | Feb 23, 2021 |
| Halsey | For profit | MKTG | — |
| Hikma | For profit | SYN | Sep 21, 1999 |
| Hikma | For profit | MKTG | Jun 5, 1979 |
| Hikma | For profit | SYN | Jun 12, 1995 |
| Hikma | For profit | NDA2 | Sep 21, 1999 |
| Ivax | For profit | MKTG | — |
| Jerome Stevens Pharmaceuticals | For profit | MKTG | Aug 31, 1998 |
| LGM Pharma | For profit | MKTG | Nov 30, 2001 |
| Laboratoires Gilbert | For profit | MKTG | — |
| Lannett Company, Inc. | For profit | SYN | Sep 13, 2012 |
| Lannett Company, Inc. | For profit | MKTG | Dec 28, 1981 |
| Larken Labs Inc | For profit | MKTG | Sep 30, 2016 |
| Leitner Pharms | For profit | MKTG | May 14, 1986 |
| Lutipold | For profit | MKTG | May 15, 2007 |
| Mallinckrodt | For profit | MKTG | Mar 27, 1985 |
| Mayne Pharma | For profit | MKTG | Mar 17, 1986 |
| Medicis | For profit | NDA2 | Mar 4, 1964 |
| Micro Labs Ltd India | For profit | MKTG | Dec 14, 2017 |
| Mikart | For profit | MKTG | Jan 21, 1987 |
| Mirror Pharms | For profit | MKTG | Dec 23, 2008 |
| Nesher Pharms | For profit | MKTG | Jul 17, 2020 |
| Nexgen Pharma, Inc | For profit | MKTG | Nov 16, 2009 |
| Nexgen Pharma, Inc | For profit | SYN | Nov 30, 2001 |
| Nostrum Laboratories | For profit | MKTG | Jun 13, 2007 |
| Novartis | For profit | NDA2 | Nov 26, 1948 |
| Novartis | For profit | MKTG | Nov 27, 1996 |
| Novast Labs | For profit | MKTG | Dec 1, 2008 |
| Nuvo Research Inc. | For profit | MKTG | Oct 28, 2016 |
| Organon | For profit | MKTG | Nov 5, 1980 |
| Perrigo | For profit | MKTG | Nov 26, 2001 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | MKTG | Mar 4, 1986 |
| Pharmaceutics International, Inc. | For profit | MKTG | Sep 22, 2016 |
| Puracap Pharmaceutical | For profit | MKTG | Apr 30, 1980 |
| Quantum Pharmaceutical | For profit | MKTG | — |
| RISE PHARMA | For profit | MKTG | Aug 13, 2021 |
| RiconPharma | For profit | MKTG | Nov 17, 2021 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Aug 29, 2012 |
| Sandoz | For profit | NDA | — |
| Sandoz | For profit | MKTG | Dec 22, 1970 |
| Sankyo | For profit | MKTG | May 15, 2007 |
| Senores Pharms | For profit | MKTG | Aug 13, 2021 |
| Shire | For profit | MKTG | Oct 1, 1986 |
| SmithKline Beecham | For profit | NDA2 | Oct 26, 1990 |
| Specgx Llc | For profit | MKTG | Jan 24, 1985 |
| Strides Pharma Science | For profit | MKTG | Sep 22, 2016 |
| Sun Pharmaceuticals | For profit | SYN | Sep 30, 2009 |
| Sun Pharmaceuticals | For profit | MKTG | Sep 30, 2009 |
| Sun Pharmaceuticals | For profit | NDA2 | Jul 7, 1958 |
| Taro Pharmaceuticals | For profit | SYN | Jul 1, 2020 |
| Taro Pharmaceuticals | For profit | MKTG | Jul 1, 2020 |
| Teva | For profit | SYN | Apr 14, 1978 |
| Teva | For profit | MKTG | Mar 29, 1985 |
| US CHEM | For profit | MKTG | — |
| Vintage | For profit | MKTG | Apr 22, 2002 |
| Vintage | For profit | SYN | Mar 5, 1999 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 21, 1978 |
| West-Ward Pharmaceutical | For profit | NDA2 | Sep 21, 1999 |
| West-Ward Pharmaceutical | For profit | MKTG | Sep 22, 2006 |
| Wraser Pharmaceuticals | For profit | MKTG | Apr 3, 2007 |
| Xanodyne Pharmaceuticals | For profit | NDA2 | Nov 12, 1957 |
| Xspire Pharma | For profit | MKTG | Aug 4, 2017 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 17, 2020 |